Sprecher
Marieke van Dalen, Aspen Oss B.V., The Netherlands
Dr Andrew Teasdale, Astra Zeneca, United Kingdom
Dr Ulrich Kissel, European QP Association, KisselPharmaConsulting, Germany
Dr Andrew Teasdale, Astra Zeneca, United Kingdom
Dr Ulrich Kissel, European QP Association, KisselPharmaConsulting, Germany
Zielsetzung
During this pre-Conference Session you will hear an update on how to deal with Nitrosamine Impurities from a GMP perspective and how to handle cases of Nitrosamine contamination in terms of filing changes/variations. You will get to know
- Which “lessons learned” future risk mitigation strategies can be based on
- How a comprehensive supply chain quality oversight should look like
- What has to be considered regarding the CEP procedure in case of Nitrosamine Impurities
You will receive first hand information from speakers representing the European QP Association and APIC.
This pre-conference session ideally complements the following 23rd APIC/CEFIC Global GMP & Regulatory API Conference.
Hintergrund
In June 2018 EU authorities were notified that a Chinese API manufacturer has detected the presence of N-nitrosodimethylamine, NDMA, in batches of Valsartan. NDMA is known to be genotoxic and carcinogenic and is classified as a Class 2A carcinogen to humans. After a referral under Article 31 of Directive 2001/83/EC the CHMP assessed the impact of the presence of this impurity on the benefit-risk balance of valsartan-containing drug products and issued a recommendation whether the concerning marketing authorisations can still be maintained or should be suspended.
Meanwhile, different Nitrosamines (NDMA, NDEA and others) were detected in almost every drug product which contains a sartan derivative as an API. Marketing Authorisation Holders have been requested to evaluate the risk of the presence of Nitrosamine impurities in human medicinal products containing chemically synthesised APIs.
Zielgruppe
This pre-conference session is of interest to all personnel involved in risk assessments of drug substances and drug products regarding potential Nitrosamine contamination. Scientific staff, Laboratory Managers, Supervisors and Analysts in pharmaceutical quality assurance and quality control departments as well as people working in the regulatory affairs area are addressed.
Programm
Nitrosamine Impurities – Lessons Learned
- Initial cause of Valsartan contamination and other causes
- Article 31 and its implications
- Where do we go from here?
How to evaluate Risks associated with Nitrosamine Impurities
- Key factors of a systematic risk based approach
- Challenges of assessing the risks of
- Drug Products
- APIs and Excipients
- Packaging Materials
- Implication of ICH M7
Nitrosamine Impurities and Supply Chain Quality Oversight
- How to deal with the challenge of complex supply chains
- What the QP has to consider
- Communication – which parties and key persons have to be involved?
Nitrosamine Impurities – handling Changes/Variations in a global Environment
- Variations/Changes as consequences to mitigate the risks
- Filing a variation/change
- Is a global approach workable?
Dieses Seminar/Webinar kann nicht gebucht werden. Alternative Termine für dieses Seminar/Webinar und ähnliche Veranstaltungen finden Sie in der Übersicht nach Thema..
Für viele Seminare und Webinare gibt es auch Aufzeichnungen, die Sie jederzeit bestellen und anschauen können. Diese Aufzeichnungen finden Sie in einer themensortierten Liste.
Oder senden Sie uns Ihre Anfrage einfach über das folgende Kontaktformular.
* auch unkompliziert per Kreditkarte bezahlbar
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
Weitere Termine online
Weitere Termine online nicht verfügbar
Aufzeichnung nicht verfügbar
Haben Sie noch Fragen?
Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de
Teilnehmerstimmen - das sagen andere über unsere Seminare: